1. Expression of the soluble domain of hSCF in HEK293 cells resulted in a highly purified glycoprotein with increased proliferative activity compared to bacteria-derived hSCF.
2. Three hybridoma clones producing monoclonal antibodies (mAbs) with high specificity for the glycoprotein were obtained and used to develop sandwich ELISA, western blot, and immunofluorescence assays.
3. Combining glycosylated rhSCF expression with hybridoma technology is a powerful strategy to obtain specific suitable immunochemical assays and thus improve glycoprotein-producing bioprocesses.
The article is generally reliable and trustworthy, as it provides evidence for its claims through experiments conducted by the authors. The article is well-structured and clearly outlines the methods used in the experiments, as well as their results. Furthermore, the article does not contain any promotional content or partiality towards any particular point of view; instead, it presents both sides equally by exploring potential risks associated with using sSCF as a biomarker or therapeutic target for various pathologies. Additionally, the article does not make any unsupported claims or missing points of consideration; instead, it provides evidence for each claim made throughout the text. The only potential issue with this article is that it does not explore counterarguments to its claims; however, this does not significantly detract from its overall reliability and trustworthiness.